PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
3.02 - 3.02
2.85 - 3.74
400 / 3.8K (Avg.)
12.58 | 0.24
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-19.43%
Negative revenue growth while IXX.DE stands at 26.87%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-18.94%
Negative gross profit growth while IXX.DE is at 48.81%. Joel Greenblatt would examine cost competitiveness or demand decline.
-22.88%
Negative EBIT growth while IXX.DE is at 152.21%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
80.36%
Operating income growth at 50-75% of IXX.DE's 119.05%. Martin Whitman would doubt the firm’s ability to compete efficiently.
279.01%
Net income growth above 1.5x IXX.DE's 174.12%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
282.78%
EPS growth above 1.5x IXX.DE's 178.38%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
282.78%
Diluted EPS growth above 1.5x IXX.DE's 178.38%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-93.25%
Dividend reduction while IXX.DE stands at 300.63%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
69.79%
OCF growth under 50% of IXX.DE's 313.37%. Michael Burry might suspect questionable revenue recognition or rising costs.
64.06%
FCF growth under 50% of IXX.DE's 1180.78%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
53.23%
5Y revenue/share CAGR at 50-75% of IXX.DE's 71.23%. Martin Whitman would worry about a lagging mid-term growth trajectory.
45.59%
3Y revenue/share CAGR 1.25-1.5x IXX.DE's 37.06%. Bruce Berkowitz might see better product or regional expansions than the competitor.
No Data
No Data available this quarter, please select a different quarter.
146.44%
5Y OCF/share CAGR above 1.5x IXX.DE's 16.59%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
124.88%
3Y OCF/share CAGR above 1.5x IXX.DE's 48.46%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
No Data
No Data available this quarter, please select a different quarter.
177.96%
Below 50% of IXX.DE's 2297.44%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
492.66%
3Y net income/share CAGR above 1.5x IXX.DE's 47.92%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
62.95%
5Y equity/share CAGR is in line with IXX.DE's 61.14%. Walter Schloss would see parallel mid-term profitability and retention policies.
60.86%
3Y equity/share CAGR above 1.5x IXX.DE's 33.77%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
-86.62%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-87.88%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
-23.72%
Firm’s AR is declining while IXX.DE shows 4.36%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-16.60%
Inventory is declining while IXX.DE stands at 0.20%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-4.17%
Negative asset growth while IXX.DE invests at 0.47%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
5.34%
Similar to IXX.DE's 5.20%. Walter Schloss finds parallel capital usage or profit distribution strategies.
-11.87%
We’re deleveraging while IXX.DE stands at 20.50%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-44.21%
We cut SG&A while IXX.DE invests at 17.48%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.